GHRP-2

GHRP-2 (a.k.a. pralmorelin) is a synthetic growth hormone secretagogue known to bind to the ghrelin/growth hormone secretagogue receptor. It was the first of the growth hormone secretagogues to be introduced and is currently marketed as a test peptide for the assessment of growth hormone deficiency and secondary adrenal failure. GHRP-2 has been investigated in stage II clinical trials for the assessment of short stature and is under active research for its effects on appetite, muscle growth, the immune system, and sleep cycles. GHRP-2 is orally and sublingually active, so it does not have to be injected to have its effects.

Source: PubChem

Sequence: D-Ala-D-2Nal-Ala-Trp-D-Phe-Lys Molecular Formula: C₄₅H₅₅N₉O₆ Molecular Weight: 817.9749 g/mol PubChem CID: 6918245 CAS Number: 158861-67-7 Code Names: KP-102, GPA-748, WAY-GPA-748

1. Protects and Enhances Muscle Structure

Research in Yaks indicates that GHRP-2 can boost muscle growth in two ways: increased protein deposition and decreased protein degradation. The research showed that GHRP-2 can overcome natural growth plateaus that occur in yaks due to food deprivation, disease, and adverse environmental conditions (e.g. cold)^[1]. The most profound finding from this study is that GHRP-2 reduces muscle atrophy by inactivating atrogin-1 and MuRF1, proteins that control the muscle degradation pathway^[2]. There is hope that these findings could be used to reduce the catabolism common in chronic illnesses like autoimmune disease, cancer, and more. Of course, by activating growth hormone and insulin-like growth factor-1, GHRP-2 helps to boost muscle protein deposition. The combined effect of reducing degradation and enhancing deposition is that GHRP-2 encourages the development of lean body mass even in adverse conditions^[3].

2. Stimulates Appetite

GHRP-2 has been shown to boost food intake^{[4], [5]}. Though this may not seem acutely important, appetite stimulation in the setting of chronic disease is an important part of overall health care. The ability to easily and reliably stimulate appetite could help doctors treat chronically ill patients and improve long-term outcomes.

Food intake in healthy adult men, placebo versus GHRP-2 Source: PubMed

3. May Protect the Heart

Research in fetal heart cell culture lines shows that GHRP-2 and its analogues (GHRP-1 and GHRP-6) can help to protect heart cells by reducing apoptosis or programmed cell death^[6]. This is of particular importance following heart attack, when heart cells are particularly prone to apoptosis thanks to decreased blood and thus nutrient supply. Research using an analogue of GHRP-2 called Hexarelin has indicated that there may be a specific receptor for these peptides^[7]. Identifying new receptors in any tissue opens pathways for new drug development, but also deepens our understanding of the human physiology and how to prevent dysfunction in the first place.

4. Improves the Immune System

GHRP-2 has been shown to stimulate the thymus, an organ responsible for protecting certain cells of the immune system. In particular., the thymus helps T cells to mature. T cells are critical for adaptive immunity and our ability to fight off complex infections. Function of the thymus declines with age, which leads to a number of age-related dysfunctions ranging from inadequate tissue repair to lost immunity and thus an inability to fight off infections, guard against cancer, and maintain normal tissue function. GHRP-2 has been shown to rejuvenate the thymus, boosting the number and diversity of T-cells it produces^[8]. This leads to improved immunity.

Change in number of active T-cells following administration of GHRP-2 Source: PubMed

5. Improves Sleep Quality

GHRP-2 has been shown to increase the duration stages 3 and 4 of the sleep cycles by about 50% each while increasing REM sleep by approximately 20% while reducing the amount that an individual deviates from “normal sleep” by as much as a third. Overall, the improvement in sleep led to improvement in cognitive function, blood pressure, healing, and energy levels^[9]. These findings, while useful to all adults, are particularly important in the elderly, where the effects of aging take a toll on sleep quality. GHRP-2 may be useful in understanding how to fine-tune sleep to improve quality and maybe even help people get all the benefits of a full night’s sleep in a fraction of the time.

6. May Affect Pain Perception

It was originally thought that observations of decreased pain in animal models of osteoarthritis were the result of GHRP-2 boosting growth hormone levels and accelerating healing in the damaged tissues. Keen scientists observed, however, that the pain relief preceded healing by a substantial margin, suggesting that GHRP-2 may have direct effects on pain perception. As it turns out, GHRP-2 has action at the opioid receptors^[10]. There are four known opioid receptors. Most opioid pain medications do not discriminate between them. This is problematic because while some of the receptors mediate pain, others affect things like wakefulness and breathing while still others impact addiction. GHRP-2 is a selective opioid receptor agonist, binding primarily to the receptors responsible for pain relief, sedation, and addiction. This finding indicates that it may be possible to produce selective opioid agonists and therefore mitigate or prevent entirely undesirable effects like respiratory depression and addiction. GHRP-2 exhibits minimal to moderate side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. GHRP-2 available from Peptide Custom is limited to educational and scientific research only, not for human consumption. For laboratory research use only.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Jean-Alain Fehrentz was born in Nancy, France, in 1955. He received his Ph.D. degree in Chemistry from the University of Nancy in 1983 and joined the Centre CNRS-INSERM de Pharmacologie Endocrinologie of Montpellier in the research group of Professor B. Castro. From 1989 to 1992 he was appointed as researcher at Sanofi Research in Montpellier. Then he moved to the Faculty of Pharmacy of Montpellier, working under the direction of Professor J. Martinez. His research interests focus onpeptide aldehydes, enzyme inhibitors, peptidomimetics, growth hormone interactions, and heterocycle based receptor ligands. He has published more than 150 scientific papers. Jean-Alain Fehrentz is being referenced as one of the leading scientists involved in the research and development of GHRP-2. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Custom and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Jean-Alain Fehrentz is listed in [11] under the referenced citations.

1. R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no. 2, p. e0149461, 2016.
2. D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.
3. L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.
4. B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,” J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005.
5. B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.
6. G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascular system,” Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000.
7. V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999.
8. D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010.
9. G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, pp. 278–286, Oct. 1997.
10. P. Zeng et al., “Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice,” Peptides, vol. 55, pp. 103–109, May 2014.
11. Moulin, A. , Ryan, J. , Martinez, J. and Fehrentz, J. (2007), Recent Developments in Ghrelin Receptor Ligands. ChemMedChem, 2: 1242-1259.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.